Prognostic Significance of Serum Uric Acid and Gamma-Glutamyltransferase in Patients with Advanced Gastric Cancer

Table 3

Multivariate analysis of primary cohort ().

			OS			PFS
			HR	95% CI		HR	95% CI
Age		0.004	1.026	1.008-1.044
NLR		0.138	1.022	0.993-1.052	0.079	1.027	0.997-1.057
DD					0.205	1.000	1.000-1.000
FIB					0.537	1.031	0.937-1.134
PLR		0.775	1.000	0.999-1.001	0.365	0.762	0.423-1.372
ALB		0.732	0.994	0.962-1.027
HDL		0.273	0.707	0.380-1.314	0.365	0.762	0.423-1.372
GGT		0.001	1.004	1.002-1.007	0.858	1.000	0.995-1.004
UA		0.012	1.002	1.000-1.004	<0.001	1.003	1.002-1.005
CEA		0.835	1.000	0.999-1.001
CA199		0.013	1.001	1.000-1.001	<0.001	1.001	1.000-1.001
Surgery	(Yes vs no)	0.509	0.862	0.555-1.339	0.456	0.859	0.576-1.281
Chemotherapy	(Yes vs no)	<0.001	0.416	0.277-0.626	0.012	0.576	0.374-0.887
Target therapy	(Yes vs no)	0.239	0.623	0.284-1.369
Lung metastasis	(Yes vs no)	0.008	2.290	1.242-4.222
Distant lymph node metastasis	(Yes vs no)	0.087	1.402	0.953-2.063
T stage					0.257	0.790	0.524-1.188
TNM stage	(IV vs III)	0.008	1.720	1.150-2.571	<0.001	2.058	1.408-3.009

Abbreviations: NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; D-D: D-dimer; FIB: fibrinogen; ALB: albumin; HDL: high-density lipoprotein; GGT: gamma-glutamyltransferase; UA: uric acid; CEA: carcino-embryonic antigen; BMI: body mass index.